Novartis AG (SWX: NOVN)
Switzerland
· Delayed Price · Currency is CHF | Market Cap | 205.21B |
| Revenue (ttm) | 43.91B |
| Net Income (ttm) | 14.53B |
| Shares Out | 2.02B |
| EPS (ttm) | 7.04 |
| PE Ratio | 23.09 |
| Forward PE | 15.14 |
| Dividend | 3.30 (3.26%) |
| Ex-Dividend Date | n/a |
| Volume | 2,437,530 |
| Open | 100.32 |
| Previous Close | 101.36 |
| Day's Range | 100.12 - 101.14 |
| 52-Week Range | 81.63 - 102.72 |
| Beta | 0.50 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 29, 2024 |
About Novartis AG
Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn ... [Read more]
Financial Performance
In 2023, Novartis AG's revenue was $46.66 billion, an increase of 7.36% compared to the previous year's $43.46 billion. Earnings were $14.85 billion, an increase of 113.52%.
Financial numbers in USD Financial StatementsNews
Novartis expands U.S. radiopharma production amid rising competition
Novartis (NVS) expands radioligand therapy production in the U.S. with two new manufacturing sites in Indianapolis and California, amid intense rivalry. Read more here.
Competitor Analysis: Evaluating Johnson & Johnson And Competitors In Pharmaceuticals Industry
In the fast-paced and cutthroat world of business, conducting thorough company analysis is essential for investors and industry experts. In this article, we will undertake a comprehensive industry com...
Natco Pharma submits ANDA for generic version of Tabrecta, a $126M US market drug
Natco Pharma Limited has submitted an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA) for a generic version of Tabrecta (Capmatinib hydrochloride). The applicati...
Comparing Merck & Co With Industry Competitors In Pharmaceuticals Industry
In today's rapidly changing and highly competitive business world, it is imperative for investors and industry observers to carefully assess companies before making investment choices. In this article...
Novartis' Cholesterol-Lowering Drug Shows Encouraging Outcome In Late-Stage Study
Wednesday, Novartis AG (NYSE: NVS) released topline results from twice-yearly Leqvio (inclisiran) in the Phase 3 V-MONO study, which met its primary endpoints. V-MONO is part of the 60,000-patient Vi...
Lindy Biosciences Enters Licensing and Collaboration Agreement With Novartis for Multi-target Drug Delivery Innovation
RALEIGH, N.C.--(BUSINESS WIRE)--Lindy Biosciences, a pioneering biotechnology company specializing in innovative drug formulation and delivery technologies, today announced a multi-target exclusive gl...
Novartis twice-yearly* Leqvio® demonstrated clinically meaningful, statistically significant LDL-C lowering as a monotherapy in patients at low or moderate ASCVD risk
Basel, August 28, 2024 – Novartis announced today positive topline results from twice-yearly* Leqvio® (inclisiran) in the Phase III V-MONO study, which met its primary endpoints. Leqvio monotherapy ac...
Galapagos Surges On An FDA Win For Its Rival To Gilead, Novartis; But There Are Some Caveats
Galapagos stock surged Monday after the Food and Drug Administration cleared the biotech company to begin testing its cancer drug in people.
Siemens Healthineers seeks €200M Novartis deal to boost cancer imaging business: FT
Siemens Healthineers (SEMHF) to acquire Novartis' (NVS) radioactive chemicals business for €200M, expanding its PET radiopharma presence. Read more here.
Siemens Healthineers to buy Novartis unit for over $223 million, FT reports
Siemens Healthineers will pay more than 200 million euros ($223.8 million) to acquire the diagnostic arm of Advanced Accelerator Applications, owned by Novartis , the Financial Times reported on Satur...
Versant Ventures and Novartis Launch Borealis Biosciences With $150 Million in Funding
–Founding investor Versant partners with Novartis to create biotech with potential to be a leading company in the field of RNA medicines for kidney disease– –Emerges from stealth with more than $150 m...
Versant Ventures and Novartis Launch Borealis Biosciences With $150 Million in Funding
VANCOUVER--(BUSINESS WIRE)--Borealis Biosciences, a next-generation RNA medicines company, today emerged from stealth with $150 million in combined Series A financing from founding investor Versant Ve...
Top 10 pharmaceutical companies in 2024: S&P Global's latest ratings and rankings
In the ever-evolving pharmaceutical landscape, financial stability and business resilience are crucial for long-term success. S&P Global, a leading financial information firm, recently released a comp...
Bristol Myers, Novartis react as Medicare prices for key drugs announced
In-Depth Analysis: Merck & Co Versus Competitors In Pharmaceuticals Industry
In the fast-paced and cutthroat world of business, conducting thorough company analysis is essential for investors and industry experts. In this article, we will undertake a comprehensive industry com...
Judge Rules Against Novartis' Effort To Halt Generic Launch Of Its Top-Selling Heart Disease Drug
Novartis AG (NYSE: NVS) reportedly faced a legal setback as it failed to convince a federal court to block MSN Pharmaceuticals from launching a generic version of its heart-failure drug, Entresto. On...
Fed court rules against Novartis in generic Entresto case: report
A federal court in Delaware has reportedly ruled against Novartis (NVS) in its quest to block the launch of a generic version of its blockbuster drug Entresto. Read more here.
Novartis loses initial bid to block generic of best-selling heart drug
Novartis failed to convince a Delaware federal court to block generic drugmaker MSN Pharmaceuticals from launching its own version of Novartis' blockbuster heart-failure drug Entresto, according to a ...
US Drugmaker Viatris Q2 Earnings Edge Out Analysts Expectation On Strong Demand For Branded And Generic Drugs
On Thursday, Viatris Inc . (NASDAQ: VTRS) reported second-quarter revenues of $3.797 billion, marginally above the consensus of $3.777 billion, up ~2% on a divestiture-adjusted operational basis . Br...
FDA Approves Expanded Use Of Novartis' Rare Disease Drug Fabhalta For Kidney Disease
On Thursday, the FDA granted accelerated approval to Novartis AG’s (NYSE: NVS) Fabhalta (iptacopan), a first-in-class complement inhibitor for the reduction of proteinuria in adults with primary immu...
Generic weight-loss drugs? They’re coming — eventually, executive says
Sandoz, the generics drugmaker spun off from Novartis, is going to get into making cheap versions of the wildly popular GLP-1 class of drugs to treat diabetes and weight loss. But it may take a while.
Novartis says FDA gives accelerated approval for kidney-disease treatment
Novartis said it received accelerated approval from the U.S. Food and Drug Administration for a treatment to bring down elevated levels of protein in the urine of adults who have a rare kidney disease...
Novartis receives FDA accelerated approval for Fabhalta® (iptacopan), the first and only complement inhibitor for the reduction of proteinuria in primary IgA nephropathy (IgAN)
Fabhalta achieved a 44% proteinuria reduction from baseline in Phase III APPLAUSE-IgAN interim analysis, compared with 9% in placebo arm, demonstrating a clinically meaningful reduction of 38% vs. pla...
Novartis gets FDA approval for Fabhalta in IgAN patients
Novartis has received FDA accelerated approval for its drug Fabhalta for the reduction of proteinuria in adults with IgAN at risk of rapid disease progression. Read more here.
US FDA approves Novartis' kidney disease drug
The U.S. Food and Drug Administration has approved the use of Novartis' drug to treat patients with a type of kidney disease, the health regulator's website showed on Wednesday.